



BILLING CODE: 3710-08

DEPARTMENT OF DEFENSE

Department of the Army

**Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing
of an Invention Concerning Antibody-Dependent Cellular Cytotoxicity (ADCC)-
Mediating Antibodies**

AGENCY: Department of the Army, DoD.

ACTION: Notice.

SUMMARY: Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/762,543, entitled “-Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies,” filed on February 8, 2013. The United States Government, as represented by the Secretary of the Army, has rights to this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619-6664, both at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: The invention relates to Antibody-Dependent cellular cytotoxicity (ADCC)-mediating antibodies, and, in particular, to ADCC-mediating antibodies (and fragments thereof) suitable for use, for example, in reducing the risk of

HIV-1 infection in a subject. The invention further relates to compositions comprising such antibodies or antibody fragments.

Brenda S. Bowen
Army Federal Register Liaison Officer

[FR Doc. 2013-30367 Filed 12/19/2013 at 8:45 am; Publication Date: 12/20/2013]